UR-144 has high affinity for the CB2 receptor with a Ki of 1.8 nM but 83x lower affinity for the CB1 receptor with a Ki of 150 nM.[3] UR-144 was found to possess an EC50 of 421 nM for human CB1 receptors, and 72 nM for human CB2 receptors.[4] UR-144 producesbradycardia and hypothermia in rats at a dose of 10 mg/kg, suggesting weak cannabinoid-like activity.[4]
Chemically it is closely related to other 2,2,3,3-tetramethylcyclopropyl synthetic cannabinoids likeA-796,260 andA-834,735 but with a different substitution on the 1-position of the indole core, in these compounds its 1-pentyl group is replaced with alkylheterocycles like 1-(2-morpholinoethyl) and 1-(tetrahydropyran-4-ylmethyl).
The UK ACMD recommended that generic prohibition legislation be extended to include UR-144 in October 2012.[5] The UK Home Office accepted the recommendation and enacted legislation to ban UR-144 as aclass B drug along with a number of other drugs on February 26, 2013 as a part ofThe Misuse of Drugs Act 1971 (Amendment) Order 2013.
UR-144 was detected in Korea, 2012. This molecule is very close to KM-X1, MN-001, YX-17 and Kr-11.[6]
UR-144 (Abbott patent) has been detected as an ingredient ofsynthetic cannabis smoking blends in New Zealand, and subsequently banned from sale as atemporary class drug on 6 April 2012.[7] It has also been encountered in smoking blends and subsequently banned in Russia.[8]
As of October 2015 UR-144 is a controlled substance in China.[9]
A forensic standard of UR-144 is available, and the compound has been posted on the Forendex website of potential drugs of abuse.[11] An ELISA immunoassay technique for detecting UR-144 in urine as part of general drug screens has been developed by Tulip Biolabs, Inc. An Homogeneous Immunoassay that runs on most Clinical Chemistry Analyzers and detects several UR and XLR synthetic cannabinoids has been developed and introduced by Immunalysis Inc. Pomona USA.
^Sobolevsky T, Prasolov I, Rodchenkov G (October 2012). "Detection of urinary metabolites of AM-2201 and UR-144, two novel synthetic cannabinoids".Drug Testing and Analysis.4 (10):745–753.doi:10.1002/dta.1418.PMID23042760.
^"关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved1 October 2015.
N
Y (what is this?)